Immediate Impact
88 standout
Citing Papers
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
2023 Standout
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
2022 Standout
Works of Angelo Secci being referenced
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Angelo Secci | 95 | 77 | 12 | 233 | 110 | 8 | 375 | |
| Marion J. Sierevogel | 191 | 2 | 28 | 133 | 83 | 6 | 414 | |
| P. Gries | 39 | 10 | 24 | 58 | 30 | 12 | 375 | |
| Philippe Dequiedt | 142 | 8 | 20 | 51 | 32 | 11 | 435 | |
| Quynh Anh Lu | 52 | 8 | 1 | 104 | 7 | 7 | 344 | |
| Edward M. McNally | 51 | 7 | 41 | 132 | 20 | 11 | 406 | |
| D. Wong | 50 | 16 | 2 | 45 | 9 | 8 | 402 | |
| Karen Lam | 270 | 3 | 10 | 88 | 11 | 9 | 413 | |
| KV Chalam | 15 | 9 | 11 | 176 | 43 | 8 | 387 | |
| Sandra E. Bendeck | 156 | 163 | 33 | 28 | 4 | 8 | 381 | |
| L Botta | 27 | 42 | 6 | 48 | 4 | 10 | 340 |
All Works
Loading papers...